Decentralized trials (DCTs) have been linked to increased participation rates of people of underserved populations.

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

The stop-work order on U.S.A.I.D.-funded research has left thousands of people with experimental drugs and devices in their ...

The removal of FDA guidance on clinical trial diversity and related anti–diversity, equity, and inclusion (DEI) actions may hinder progress toward equitable health care, impacting workforce diversity, ...

Anti-LGBTQI+ public policies overwhelmingly target youth and young adults, disrupting access to educational opportunities, ...

With the FDA quietly rolling back DEI initiatives under Trump’s latest executive order, experts warn that underrepresentation ...

Female participation also rose significantly from 49.0% to 55.7% and is more representative with the total U.S. population ... in clinical research, accelerating medicines for thousands of conditions ...

This unified approach enables sponsors to access a wider patient population ... to be major challenges in clinical research,” said Josh Rose, CEO of Hawthorne Health. “This partnership ...

Hawthorne Health and RxE2 have announced a strategic partnership to transform community-based clinical trial delivery.